ATE315567T1 - A-1-adenosin rezeptor antagoniste - Google Patents
A-1-adenosin rezeptor antagonisteInfo
- Publication number
- ATE315567T1 ATE315567T1 AT97947567T AT97947567T ATE315567T1 AT E315567 T1 ATE315567 T1 AT E315567T1 AT 97947567 T AT97947567 T AT 97947567T AT 97947567 T AT97947567 T AT 97947567T AT E315567 T1 ATE315567 T1 AT E315567T1
- Authority
- AT
- Austria
- Prior art keywords
- integer ranging
- adenosine receptor
- formula
- receptor antagonist
- cooh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/753,048 US5786360A (en) | 1996-11-19 | 1996-11-19 | A1 adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE315567T1 true ATE315567T1 (de) | 2006-02-15 |
Family
ID=25028936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97947567T ATE315567T1 (de) | 1996-11-19 | 1997-11-19 | A-1-adenosin rezeptor antagoniste |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US5786360A (de) |
| EP (2) | EP1790651A1 (de) |
| JP (1) | JP2001504491A (de) |
| AT (1) | ATE315567T1 (de) |
| AU (1) | AU5261598A (de) |
| CA (1) | CA2264721C (de) |
| DE (1) | DE69735108D1 (de) |
| WO (1) | WO1998022465A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| US5786360A (en) * | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| JP3563938B2 (ja) | 1997-09-29 | 2004-09-08 | キヤノン株式会社 | 画像読取装置及びその制御方法 |
| US6117445A (en) * | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
| US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| ES2269217T3 (es) | 1999-12-02 | 2007-04-01 | Osi Pharmaceuticals, Inc. | Compuestos especificos para los receptores a1, a2a y a3 de adenosina y sus usos. |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6998404B2 (en) * | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンa1及びa3受容体に特異的な化合物とその使用 |
| JP2005516917A (ja) | 2001-12-12 | 2005-06-09 | アメリカ合衆国 | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 |
| DE60236458D1 (de) | 2001-12-20 | 2010-07-01 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 a₂b 선택성 길항 화합물, 그의 합성 방법 및용도 |
| JP2006518390A (ja) * | 2003-02-19 | 2006-08-10 | エンダシア,インコーポレイテッド | A1アデノシンレセプターアンタゴニスト |
| US20110282031A1 (en) * | 2003-06-06 | 2011-11-17 | Wilson Constance N | A1 adenosine receptor diagnostic probes |
| EP1636229A4 (de) * | 2003-06-06 | 2008-07-30 | Endacea Inc | A1-adenosinrezeptorantagonisten |
| EP1636230A4 (de) * | 2003-06-09 | 2010-06-16 | Endacea Inc | A1-adenosinrezeptorantagonisten |
| WO2006099204A1 (en) * | 2005-03-11 | 2006-09-21 | Aderis Pharmaceuticals, Inc. | Substituted 9-alkyladenines and the use thereof |
| US7696211B2 (en) * | 2005-04-29 | 2010-04-13 | Wilson Constance N | Methods and pharmaceutical compositions for treating sepsis |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| EP2001881A2 (de) * | 2006-03-07 | 2008-12-17 | Endacea, Inc. | Zusammensetzungen und verfahren zur behandlung von atmungsstörungen |
| US20090048155A1 (en) | 2007-08-15 | 2009-02-19 | Endacea, Inc. | Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection |
| JP5603248B2 (ja) | 2007-12-21 | 2014-10-08 | エンダセア, インコーポレイテッド | A1アデノシン受容体アンタゴニスト |
| US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| US9877967B2 (en) | 2010-01-26 | 2018-01-30 | Endacea, Inc. | Methods and pharmaceutical compositions for preventing and treating renal impairment |
| US20130183696A1 (en) | 2010-09-15 | 2013-07-18 | Constance Neely Wilson | Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay |
| RU2018145734A (ru) | 2016-06-08 | 2020-07-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения в качестве ингибиторов atf4 пути |
| JP2019536460A (ja) | 2016-12-03 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Car−t細胞の調節方法 |
| US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| IL327498A (en) | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| EP3724225A1 (de) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5-bindende moleküle und verfahren zur verwendung davon |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| EP4427810A3 (de) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Behandlungsverfahren mit adoptiver zelltherapie |
| EA202192103A1 (ru) | 2019-01-29 | 2021-12-15 | Джуно Терапьютикс, Инк. | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Cd19標的car t細胞のセカンドライン治療のための処置方法 |
| EP4565262A2 (de) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimäre antigenrezeptoren spezifisch für gprc5d und bcma |
| US20260207667A1 (en) | 2022-12-13 | 2026-07-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317533A (en) * | 1967-05-02 | Theophylline derivatives | ||
| BE636828A (de) * | ||||
| US2887468A (en) * | 1954-03-11 | 1959-05-19 | Eastman Kodak Co | Copolyesters of a glycol, a dicarboxylic acid and a hydroxy carboxylic acid |
| US2887486A (en) | 1956-10-29 | 1959-05-19 | S E Massengill Company | Theophylline derivatives |
| US3317433A (en) | 1958-10-23 | 1967-05-02 | Ncr Co | Heat rupturable capsules |
| DE1245383B (de) | 1960-04-22 | 1967-07-27 | Manuf De Produits Pharma A Chr | Verfahren zur Herstellung von in 7-Stellung basisch substituierten 8-Benzyltheophyllinderivaten |
| GB947495A (en) | 1960-04-22 | 1964-01-22 | Manuf Prod Pharma | New derivatives of dialkyl xanthines and the preparation thereof |
| US3031451A (en) | 1960-07-21 | 1962-04-24 | Endo Lab | Salt of nicotinic acid |
| US3309271A (en) * | 1963-08-30 | 1967-03-14 | Manuf Prod Pharma | Methods and composition for inducing choleresis |
| AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| US4092417A (en) | 1976-12-08 | 1978-05-30 | Johann A. Wulfing | Theophylline salts of 5-methylisoxazole-3-carboxylic acid |
| DE2659241A1 (de) | 1976-12-23 | 1978-07-06 | Josef Dipl Chem Dr Rer N Klosa | Xanthinol-orotat |
| SE7810947L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
| EP0011399A1 (de) | 1978-11-11 | 1980-05-28 | FISONS plc | N-Substituierte Theophylline, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
| IT1195267B (it) | 1980-04-15 | 1988-10-12 | Abc Ist Biolog Chem Spa | Derivati teofillinmetildiossolanici,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| DE3120909C2 (de) | 1980-06-05 | 1986-01-02 | A. Christiaens S.A., Brüssel/Bruxelles | Verfahren zur Herstellung von 7-(N-Äthyl-N-β-hydroxyäthylaminoäthyl)-8-benzyltheophyllin (Bamifyllin) |
| DE3028273A1 (de) | 1980-07-25 | 1982-02-25 | Fa. Dr. Willmar Schwabe, 7500 Karlsruhe | Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate |
| US4769377A (en) | 1983-02-18 | 1988-09-06 | The Johns Hopkins University | Adenosine receptor antagonists |
| US5248770A (en) * | 1984-10-26 | 1993-09-28 | The United States Of America, As Represented By The Department Of Health And Human Services | Molecular probes for adenosine receptors |
| US4612315A (en) * | 1984-10-26 | 1986-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives |
| US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
| US4772607A (en) | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| IT1197516B (it) | 1986-12-24 | 1988-11-30 | Abc Ist Biolog Chem Spa | Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono |
| US4968672A (en) * | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
| US5066655A (en) | 1987-04-24 | 1991-11-19 | Whitby Research, Inc. | N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| US5192740A (en) * | 1987-12-21 | 1993-03-09 | University Of Alberta | Compositions and methods for improving cold tolerance in animals and humans |
| US5032593A (en) | 1988-07-01 | 1991-07-16 | Marion Merrell Dow Inc. | Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines |
| US5298508A (en) * | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| JP2843634B2 (ja) * | 1989-03-06 | 1999-01-06 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| US4971972A (en) * | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
| US5256650A (en) | 1989-03-29 | 1993-10-26 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| IT1240843B (it) | 1990-05-24 | 1993-12-17 | Malesci Istituto Farmacobiologico | Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione. |
| CA2061544A1 (en) * | 1991-02-25 | 1992-08-26 | Fumio Suzuki | Xanthine compounds |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| EP0541120B1 (de) * | 1991-11-08 | 1999-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivate zur Behandlung der Demenz |
| JP2928386B2 (ja) * | 1992-07-08 | 1999-08-03 | 協和醗酵工業株式会社 | うつ病治療剤 |
| TW252044B (de) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| US5340813A (en) * | 1992-11-09 | 1994-08-23 | Cell Therapeutics, Inc. | Substituted aminoalkyl xanthine compounds |
| US5395836A (en) * | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
| DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US5786360A (en) * | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
-
1996
- 1996-11-19 US US08/753,048 patent/US5786360A/en not_active Expired - Lifetime
-
1997
- 1997-11-19 DE DE69735108T patent/DE69735108D1/de not_active Expired - Lifetime
- 1997-11-19 US US09/269,055 patent/US6489332B1/en not_active Expired - Fee Related
- 1997-11-19 EP EP06000239A patent/EP1790651A1/de not_active Withdrawn
- 1997-11-19 EP EP97947567A patent/EP0946557B1/de not_active Expired - Lifetime
- 1997-11-19 CA CA002264721A patent/CA2264721C/en not_active Expired - Fee Related
- 1997-11-19 JP JP52380798A patent/JP2001504491A/ja not_active Ceased
- 1997-11-19 AU AU52615/98A patent/AU5261598A/en not_active Abandoned
- 1997-11-19 WO PCT/US1997/021045 patent/WO1998022465A1/en not_active Ceased
- 1997-11-19 AT AT97947567T patent/ATE315567T1/de not_active IP Right Cessation
-
1998
- 1998-04-15 US US09/060,527 patent/US6117998A/en not_active Expired - Fee Related
-
2000
- 2000-05-03 US US09/564,011 patent/US6495687B1/en not_active Expired - Fee Related
-
2002
- 2002-02-27 US US10/083,836 patent/US20020082269A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6495687B1 (en) | 2002-12-17 |
| US20020082269A1 (en) | 2002-06-27 |
| EP0946557B1 (de) | 2006-01-11 |
| US6117998A (en) | 2000-09-12 |
| US6489332B1 (en) | 2002-12-03 |
| AU5261598A (en) | 1998-06-10 |
| JP2001504491A (ja) | 2001-04-03 |
| CA2264721C (en) | 2006-07-04 |
| WO1998022465A1 (en) | 1998-05-28 |
| CA2264721A1 (en) | 1998-05-28 |
| US5786360A (en) | 1998-07-28 |
| DE69735108D1 (de) | 2006-04-06 |
| EP0946557A1 (de) | 1999-10-06 |
| EP1790651A1 (de) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69735108D1 (de) | A-1-adenosin rezeptor antagoniste | |
| UA37230C2 (uk) | Полі-1-н-алкенаміни та склади палива або мастильного засобу, що їх містять | |
| IL164967A0 (en) | Use of estrogen antagonists and estrogen agonists in the preparation of medicament for inhibiting pathological conditions | |
| GB2346878A (en) | Preparation of 3-substituted adenines | |
| GR3021581T3 (en) | Vitamin D compounds and method of preparing these compounds. | |
| DK0918776T3 (da) | Totalsyntese af antitumor acylfulvener | |
| PT806416E (pt) | Derivados de huperzina a sua preparacao e utilizacao | |
| TW427979B (en) | A condensed piperidine compound | |
| ATE206418T1 (de) | 1-benzolsulfonylpyrrolidinderivate als bradykinin rezeptor antagonisten | |
| ES2074828T3 (es) | Copoliester degradable de 4-hidroxi-prolina y composicion farmaceutica que lo contiene. | |
| DE69734952D1 (de) | Anilide als ACAT-Hemmer | |
| PT894787E (pt) | Derivados de feniletanolaminotetralinocarboxilato 3,4-dissubstituidos | |
| TR200002803T2 (tr) | MRP1 inhibe etmek için yöntemler. | |
| BR9901201A (pt) | Composto de titanato | |
| TR200002804T2 (tr) | MRP1 inhibe etmek için yöntemler | |
| FR2655039B1 (fr) | Synthese des bromures de perfluoroalkyle. | |
| PL341837A1 (en) | Novel tricyclic compounds, method of obtaining them and pharmacological compositions containing such compounds | |
| TW222273B (de) | ||
| WO2004110379A3 (en) | A1 adenosine receptor antagonists | |
| DK1001950T3 (da) | Fluorerede triazinmonomerer | |
| DE69615814D1 (de) | Uch-15-verbindungen | |
| IT1272881B (it) | Composti arilalchilenici | |
| AR008318A1 (es) | Composiciones de detergentes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |